AI assistant
JOHNSON & JOHNSON — Director's Dealing 2005
Feb 15, 2005
29750_dirs_2005-02-15_ae2d3302-4e43-48a9-be31-7d58c5edb804.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BARRIER THERAPEUTICS INC (BTRX)
CIK: 0001173657
Period of Report: 2005-02-15
Reporting Person: JOHNSON & JOHNSON (10% Owner)
Reporting Person: JOHNSON & JOHNSON DEVELOPMENT CORP ET AL (10% Owner)
Reporting Person: Johnson & Johnson Consumer Companies, Inc. (10% Owner)
Reporting Person: Janssen Pharmaceutica Products, L.P. (10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2005-02-15 | Common Stock | S | 694327 | $19.50 | Disposed | 3753749 | Indirect |
Footnotes
F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by the following wholly-owned subsidiaries of the Reporting Person: Johnson & Johnson Development Corporation ("JJDC") (selling 25,000 shares of Common Stock); Johnson & Johnson Consumer Companies, Inc. ("JJCC") (selling 160,638 shares of Common Stock); and Janssen Pharmaceutica Products, L.P. ("JPP") (selling 508,689 shares of Common Stock). Following the reported sale, JJDC will own 256,410 shares of Common Stock; JJCC will own 856,028 shares of Common Stock; and JPP will own 2,641,311 shares of Common Stock.